News
NICE recommends Janssen’s treatment for active psoriatic arthritis
Tremfya – also known as guselkumab – has been recommended by the National Institute for Health and Care Excellence (NICE) for people with active psoriatic arthritis whose disease does not respond to conventional disease-modifying anti-rheumatic drugs (DMARDs).